Cefpirome versus ceftazidime in the treatment of urinary tract infections

• Published in: Journal of antimicrobial chemotherapy 1992-04, Vol.29 (suppl-A), p.95-104
• Main Author: Study Group
• Format: Article
• Language: English
• Subjects: Cefpirome; Ceftazidime - adverse effects; Ceftazidime - therapeutic use; Cephalosporins - adverse effects; Cephalosporins - therapeutic use; Drug Administration Schedule; Female; Gram-Negative Bacterial Infections - drug therapy; Gram-Positive Bacterial Infections - drug therapy; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Middle Aged; Urinary Tract Infections - drug therapy
• ISSN: 0305-7453; 1460-2091
• DOI: 10.1093/jac/29.suppl_A.95

In an open, randomized multiclinic trial, hospitalized patients with upper or complicated lower urinary tract infections requiring treatment with a parenteral antibiotic were randomized to receive 1 g doses of cefpirome (594 patients) or ceftazidime (303 patients) 12 hourly for at least five days. Cefpirome was considerably more active in vitro than ceftazidime against Gram-positive pathogens isolated from the urine samples. At the early follow-up, 2–15 days after treatment, clinical cure was achieved in 86% and 82% of the patients in the cefpirome and ceftazidime groups respectively. Elimination of the causative pathogen without recurrence or early reinfection was achieved in 87% of the patients in both groups. Drug related adverse events occurred in 8·9% of cefpirome treated patients and in 4·6% of those receiving ceftazidime. No specific type of adverse reaction accounted for this difference. Treatment was discontinued because of adverse events in 2·5% and 1·7% of the patients respectively. Cefpirome was found to be safe and at least as effective as ceftazidime for the treatment of urinary tract infections in hospitalized patients.